Undisclosed DR3 bispecific antibody
/ Shattuck
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 06, 2025
Shattuck continues to develop multiple preclinical DR3-based bispecific antibodies...
(Shattuck Labs Press Release)
- "Shattuck plans to announce a lead bispecific candidate from its preclinical pipeline in the first half of 2026."
Pipeline update • Inflammatory Bowel Disease
August 14, 2025
Shattuck continues to develop multiple preclinical DR3-based bispecific antibodies
(GlobeNewswire)
- "Shattuck plans to nominate a lead bispecific candidate from its preclinical pipeline in 2025."
Pipeline update • Inflammatory Bowel Disease
1 to 2
Of
2
Go to page
1